US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

266.00

-13.0200-4.67%

Post-market: 264.12-1.8800-0.71%19:53 EDT

Volume:290.13K

Turnover:77.49M

Market Cap:498.61M

PE:- -

High:274.71

Open:269.37

Low:260.01

Close:279.02

52wk High:341.93

52wk Low:74.95

Shares:1.87M

Float Shares:1.87M

Volume Ratio:0.94

T/O Rate:15.48%

Dividend:1.00

Dividend Rate:0.38%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

EBR Systems Says FDA Finds No Need for WiSE System Recall After Cybersecurity Incident

MT Newswires Live

Press Release: Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting

Echo IQ's EchoSolv HF Device Deemed 'Not Substantially Equivalent' by US FDA

MT Newswires Live

Health Care Down as Novartis, Boston Scientific Weigh - Health Care Roundup

Tenet Healthcare Prices Upsized $2 Billion Notes Offering

MT Newswires Live

Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference

Health Care Roundup: Market Talk

Intellia’s Lonvo-z Gains FDA Priority Review for HAE

Cycurion Secures New Healthcare and Public Health Contracts

Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform

ICU Girişim Sermayesi Details Diversified Venture Portfolio in Healthcare and Technology

Dennis Ding Reiterates Buy on Tarsus, Highlighting Robust Xdemvy Trends, Conservative 2026 Guidance, and Attractive Valuation Backed by Late-Stage Pipeline

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged

Health Care Roundup: Market Talk

HCA Healthcare Delivers Consistent Message Around H2 Cadence Expectations, RBC Says

MT Newswires Live

RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio

Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and MiMedx Group (MDXG)

Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/LABU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":266,"timestamp":1789070400000,"preClose":279.02,"halted":0,"volume":290130,"hourTrading":{"tag":"盘后","latestPrice":264.12,"preClose":266,"latestTime":"19:53 EDT","volume":1904,"amount":504475.6573,"timestamp":1789084425326,"change":-1.88,"changeRate":-0.007068,"amplitude":0.00782},"delay":0,"changeRate":-0.046663321625689855,"floatShares":1874486,"shares":1874486,"eps":0,"marketStatus":"Closed","change":-13.02,"latestTime":"09-10 16:00:00 EDT","open":269.37,"high":274.705,"low":260.01,"amount":77488111.8858,"amplitude":0.052666,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789113600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":279.02,"sharesOutstanding":3074486,"nav":278.651,"aum":522328218.83,"dividendRate":0.003776,"bidAskSpread":0.002964,"preHourTrading":{"tag":"盘前","latestPrice":268.99,"preClose":279.02,"latestTime":"09:29 EDT","volume":1828,"amount":503835.0052,"timestamp":1789046962415,"change":-10.03,"changeRate":-0.035947,"amplitude":0.054249},"postHourTrading":{"tag":"盘后","latestPrice":264.12,"preClose":266,"latestTime":"19:53 EDT","volume":1904,"amount":504475.6573,"timestamp":1789084425326,"change":-1.88,"changeRate":-0.007068,"amplitude":0.00782},"volumeRatio":0.944317,"impliedVol":0.9105,"impliedVolPercentile":0.502},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1874486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.944317,"shares":1874486,"dividePrice":1.0045,"high":274.705,"amplitude":0.052666,"preClose":279.02,"low":260.01,"week52Low":74.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":266,"eps":0,"divideRate":0.003776,"volume":290130,"delay":0,"ttmEps":0,"open":269.37,"prevYearClose":159.39,"prevWeekClose":303.55,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":311.81,"twentyDayClose":286.75,"sixtyDayClose":188.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666630529","title":"EBR Systems Says FDA Finds No Need for WiSE System Recall After Cybersecurity Incident","url":"https://stock-news.laohu8.com/highlight/detail?id=2666630529","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666630529?lang=en_us&edition=fundamental","pubTime":"2026-09-09 09:02","pubTimestamp":1788915728,"startTime":"0","endTime":"0","summary":"EBR Systems  said the US Food and Drug Administration  has completed its review of the company's cybersecurity risk assessment related to the February incident and determined that no field corrective action or recall of the WiSE System is warranted, according to a Wednesday filing with the Australian bourse.The incident was classified as a controlled risk under FDA postmarket cybersecurity guidance, with no evidence of any impact on the safety or performance of fielded WiSE cardiac resynchronization therapy systems, per the filing.The company continues its cybersecurity remediation efforts by strengthening credential controls, enhancing anti-phishing measures, expanding endpoint monitoring, hardening its products, and providing required updates to the FDA, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","NTSK","HAKY","BUG","BK4097","EBR.AU","TEKX","BK4588","CIBR","LABU","HACK","BK7007","IHAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370726","title":"Press Release: Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370726?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:59","pubTimestamp":1788904740,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (\"Inhibitor\" or the \"Company\") today highlighted several important developments disclosed in its Quarterly Re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","BK4022","BK4588","BK4539","BK4139","R","BK4232","INTI","LENZ","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370799","title":"Echo IQ's EchoSolv HF Device Deemed 'Not Substantially Equivalent' by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370799","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:58","pubTimestamp":1788904705,"startTime":"0","endTime":"0","summary":"Echo IQ  failed to secure commercial clearance for its EchoSolv HF device after the US Food and Drug Administration  found its initial 510 application  \"not substantially equivalent,\" according to an Australian bourse filing on Tuesday after market hours.The company is evaluating the US FDA's concerns with regulatory, legal, and statistical advisers and believes a potential pathway to clearance remains, per the filing.An applicant whose medical device has been deemed not substantially equivalent may resubmit another 510 application with new data, request a Class I or II designation, file a reclassification petition, or submit a premarket approval application, according to the FDA's website.The decision does not affect the FDA-cleared EchoSolv AS platform or its commercialization in the US, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","EIQ.AU","BK7016","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666704053","title":"Health Care Down as Novartis, Boston Scientific Weigh - Health Care Roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2666704053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666704053?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:31","pubTimestamp":1788903060,"startTime":"0","endTime":"0","summary":"Health-care companies fell after growth warnings from two major medical-device makers and a disappointing clinical trial.Shares of Novartis plunged after one of the company's leading drug candidates failed to show significant progress on a late-stage trial on sufferers of a neuromuscular condition.Medical-device maker Boston Scientific said it likely would not meet its financial guidance due to the cyberattack that has disrupted its operations.Shares of Stryker declined after the maker of orthopedic implants and other medical technology said a lack of supply continues to hamper its peripheral vascular business.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2112291526.USD","LU2362541513.USD","IE00B2B36J28.USD","LU0225283273.USD","LU1291159041.SGD","BK4585","IE0009355771.USD","LU1983299246.USD","LU0267386448.USD","BK4504","XBI","SG9999001176.SGD","LU2324357040.USD","LU1023059063.AUD","LU2506951958.HKD","LU2362540622.SGD","BK4581","IE00B4R5TH58.HKD","LU1989764664.SGD","LU2357305700.SGD","BSX","LU0122379950.USD","LU0251132253.USD","LU0353189680.USD","LU1720051108.HKD","IE00BFTCPJ56.SGD","SG9999001176.USD","LU0048584097.USD","LU1791710400.SGD","IE00BJT1NW94.SGD","LU1153585028.USD","LU2491050071.SGD","LABU","LU1791710582.SGD","SGXZ57979304.SGD","LU0138981039.USD","LU0823417737.USD","LU2242649171.HKD","LU1548497426.USD","LU0345769631.USD","LU1989771016.USD","LU0238689110.USD","LU0882574055.USD","LU2491049909.HKD","LU0266013472.USD","LU0823417653.USD","LU0187121727.USD","BK4082","LU1989764748.USD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370464","title":"Tenet Healthcare Prices Upsized $2 Billion Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370464","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370464?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:28","pubTimestamp":1788902911,"startTime":"0","endTime":"0","summary":"Tenet Healthcare  priced a private offering of $2 billion in senior notes due Sept. 15, 2034, bearing interest at 6.250% per annum, the company said late Tuesday.The offering was upsized from a previously announced $1.5 billion, with completion expected Sept. 22, the company said.Tenet said proceeds, along with cash on hand, will fund redemption of $1.5 billion of its 5.125% notes due 2027 and partial redemption of $500 million of its 6.125% notes due 2028.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0029874061.USD","LU1201861165.SGD","LU2324357040.USD","BK4588","XBI","THC","XLV","LABU","LU0963586101.USD","BK4185","LU0130103400.USD","LU0128526141.USD","LU0648000940.SGD","THC.AU","BK4137","BK4585","BK4581","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666689370","title":"Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666689370","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666689370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:05","pubTimestamp":1788901500,"startTime":"0","endTime":"0","summary":"NEW YORK, Sept.  08, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 2026 Jefferies Healthcare Ser","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3358168/0/en/strata-critical-to-present-at-the-2026-jefferies-healthcare-services-and-technology-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","LABU","BK4585","HCSG","BK4581","XLV","BK4588","LU0029874061.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370898","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370898","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370898?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:50","pubTimestamp":1788900600,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0417 ET - Novartis's latest clinical-trial failure suggests the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LABU","XLV","BK4588","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666772143","title":"Intellia’s Lonvo-z Gains FDA Priority Review for HAE","url":"https://stock-news.laohu8.com/highlight/detail?id=2666772143","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666772143?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:35","pubTimestamp":1788899708,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics ( ($NTLA) ) has shared an update. On September 8, 2026, Intellia Therapeutics announced that the U.S. Food and Drug Administr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellias-lonvo-z-gains-fda-priority-review-for-hae?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellias-lonvo-z-gains-fda-priority-review-for-hae?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1169589451.USD","BK4585","LABU","IE0034390439.USD","LU0106261612.USD","IE00B64QTZ34.USD","LU0205193047.USD","BK4588","LU1169590202.USD","LU0205194284.USD","IE00BLDYK493.USD","BK4198","HAE","IE00B19Z6F94.USD","LU0012050646.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372275","title":"Cycurion Secures New Healthcare and Public Health Contracts","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372275","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372275?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:47","pubTimestamp":1788896876,"startTime":"0","endTime":"0","summary":"Cycurion ( ($CYCU) ) has shared an update. On September 3, 2026, Cycurion announced new engagements totaling about $800,000 in annual contract spen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cycurion-secures-new-healthcare-and-public-health-contracts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cycurion-secures-new-healthcare-and-public-health-contracts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LABU","BK4137","BK4585","CYCU","HCSG","XBI","LU0029874061.USD","XLV","BK4581","BK4123","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666372293","title":"Analyst Maintains Buy on Sarepta, Keeping $35 Price Target Amid Confidence in DM1 Franchise and α‑Integrin Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2666372293","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666372293?lang=en_us&edition=fundamental","pubTime":"2026-09-09 03:45","pubTimestamp":1788896725,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yun Zhong from Wedbush maintained a Buy ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-sarepta-keeping-35-price-target-amid-confidence-in-dm1-franchise-and-integrin-delivery-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-sarepta-keeping-35-price-target-amid-confidence-in-dm1-franchise-and-integrin-delivery-platform-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666273374","title":"ICU Girişim Sermayesi Details Diversified Venture Portfolio in Healthcare and Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2666273374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666273374?lang=en_us&edition=fundamental","pubTime":"2026-09-09 02:12","pubTimestamp":1788891143,"startTime":"0","endTime":"0","summary":"ICU Girisim Sermayesi Yatirim Ortakligi A.S. ( ($TR:ICUGS) ) has provided an announcement. ICU Girişim Sermayesi Yatırım Ortaklığı A.Ş. has detaile...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/icu-girisim-sermayesi-details-diversified-venture-portfolio-in-healthcare-and-technology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/icu-girisim-sermayesi-details-diversified-venture-portfolio-in-healthcare-and-technology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0029874061.USD","XLV","LABU","HCSG","BK4585","BK4588","LU0128526141.USD","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374136","title":"Dennis Ding Reiterates Buy on Tarsus, Highlighting Robust Xdemvy Trends, Conservative 2026 Guidance, and Attractive Valuation Backed by Late-Stage Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374136","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374136?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:55","pubTimestamp":1788890117,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Dennis Ding from Jefferies reiterated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/dennis-ding-reiterates-buy-on-tarsus-highlighting-robust-xdemvy-trends-conservative-2026-guidance-and-attractive-valuation-backed-by-late-stage-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/dennis-ding-reiterates-buy-on-tarsus-highlighting-robust-xdemvy-trends-conservative-2026-guidance-and-attractive-valuation-backed-by-late-stage-pipeline-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","XLV","BK4581","XBI","BK4585","TARS","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374637","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374637?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:20","pubTimestamp":1788888012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and BioCryst (BCRX) with b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4547","XBI","LABU","XLV","LFSC","BCRX","LU0128526141.USD","HCSG","LU0029874061.USD","BK4585","BK4581","BK4588","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275371","title":"Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275371?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:40","pubTimestamp":1788885608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on enGene Holdings (ENGN) and Structure Therapeutics, I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","HCSG","BK4599","SAPH","XLV","DIVL","LU0128526141.USD","AADR","XBI","ENGN","CVY","LU0029874061.USD","BK4588","BK4137","ARMH","BK4581","BK4585","LABU","DINT","GPCR","BK4139","APIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371411","title":"Sell Rating Reaffirmed on Weakening Core Franchise and Elevated Clinical Risk; $5 Price Target Unchanged","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371411?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:35","pubTimestamp":1788885338,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mitchell Kapoor from H.C. Wainwright rei...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/sell-rating-reaffirmed-on-weakening-core-franchise-and-elevated-clinical-risk-5-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/sell-rating-reaffirmed-on-weakening-core-franchise-and-elevated-clinical-risk-5-price-target-unchanged-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LABU","XLV","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666371944","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2666371944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666371944?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:20","pubTimestamp":1788884400,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0417 ET - Novartis's latest clinical-trial failure suggests the ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4581","XLV","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665737976","title":"HCA Healthcare Delivers Consistent Message Around H2 Cadence Expectations, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2665737976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665737976?lang=en_us&edition=fundamental","pubTime":"2026-09-08 23:43","pubTimestamp":1788882197,"startTime":"0","endTime":"0","summary":"HCA Healthcare's (HCA) management delivered a consistent message around second-half cadence expectations, with a more difficult comparison ahead for Q3 and a relatively more favorable comparison for Q","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0985489474.SGD","LU1119994496.HKD","LU0878866978.SGD","LU0648001328.SGD","LU2244417387.USD","BK4588","LU0310799852.SGD","LU0114720955.EUR","BK4185","LU1261432733.SGD","LU1150488218.USD","LU0433182093.SGD","LU1489326972.SGD","BK4504","BK4585","IE00B3S45H60.SGD","LU1201861249.SGD","XLV","LU0882574055.USD","SG9999014021.USD","HCA","SG9999014013.SGD","LU0203347892.USD","LU0128525929.USD","LU0068578508.USD","LU1267930490.SGD","LU2355687059.USD","LU0980610538.SGD","LU0708994859.HKD","SG9999014005.SGD","LU1084165304.USD","XBI","LU0130102774.USD","LU1267930573.SGD","LU1150488135.SGD","LABU","LU0310800379.SGD","IHF","LU0203345920.USD","SG9999014039.USD","LU0211328371.USD","LU0029864427.USD","BK4581","LU0211327993.USD","LU0187121727.USD","IE00B775SV38.USD","LU0868494617.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665793803","title":"RedHill Biopharma Pushes for Growth Securing Rights to Ferring’s $37M Gastrointestinal Drugs Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2665793803","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665793803?lang=en_us&edition=fundamental","pubTime":"2026-09-08 22:49","pubTimestamp":1788878982,"startTime":"0","endTime":"0","summary":"RedHill Biopharma ($RHDL) has said the acquisition from Ferring of commercialization rights to two established gastrointestinal (GI) FDA-approved d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/redhill-biopharma-pushes-for-growth-securing-rights-to-ferrings-37m-gastrointestinal-drugs-portfolio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/redhill-biopharma-pushes-for-growth-securing-rights-to-ferrings-37m-gastrointestinal-drugs-portfolio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375964","title":"Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and MiMedx Group (MDXG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375964","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375964?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:20","pubTimestamp":1788873611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Establishment Labs Holdings (ESTA) and MiMedx Group ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-establishment-labs-holdings-esta-and-mimedx-group-mdxg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-establishment-labs-holdings-esta-and-mimedx-group-mdxg-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4585","LU2324357040.USD","MDXG","ESTA","BK4137","HCSG","XBI","BK4581","XLV","BK4139","BK4588","LU0029874061.USD","LABU","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665013373","title":"Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums","url":"https://stock-news.laohu8.com/highlight/detail?id=2665013373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665013373?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:15","pubTimestamp":1788873300,"startTime":"0","endTime":"0","summary":"Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357752/0/en/akari-therapeutics-selected-to-showcase-novel-ph1-adc-payload-platform-at-leading-global-oncology-adc-and-healthcare-forums.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNGR","LENZ","BK4581","HCSG","XBI","XLV","BK4139","LABU","BK4588","LU0128526141.USD","BK4007","LU0029874061.USD","BK4585","BK4539","IEIH","BK4137","CST"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":5,"totalSize":412,"code":"91000000","status":"200"}]}}